 |
Practical Approaches to Vascular Complications in Systemic Sclerosis (SSc) CME Richard M. Silver, MD, Chair; Richard N. Channick, MD, FCCP; Kristin B. Highland, MD; Myung H. Park, MD, FACC; Robert W. Simms, MD Author Information and Disclosures Release Date: February 25, 2008; Valid for credit through February 25, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Practical Approaches to Vascular Complications in Systemic Sclerosis (SSc)" symposium held in Boston, Massachusetts, on November 11, 2007.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details Contents of This CME Activity- Welcome and IntroductionRichard M. Silver, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Vasculopathies in Scleroderma: Basic Science Update and Clinical CorollariesRobert W. Simms, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Early Diagnosis and Critical Risk Assessment in SSc-related Lung ComplicationsKristin B. Highland, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Early Intervention in PAH: Current Strategies and New Clinical Trial EvidenceRichard N. Channick, MD, FCCPAvailable As: Slides/Audio | Slides/Transcript | Audio
- Long-term Goals and Emerging Combination Treatment Paradigms in PAHMyung H. Park, MD, FACCAvailable As: Slides/Audio | Slides/Transcript | Audio
- Panel DiscussionRichard M. Silver, MD, Robert W. Simms, MD, Kristin B. Highland, MD, Richard N. Channick, MD, FCCP, Myung H. Park, MD, FACCAvailable As: Slides/Audio | Slides/Transcript | Audio
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medical Education Resources |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Identify vasculopathies associated with systemic sclerosis (SSc), describe pathogenic pathways, and delineate clinical corollaries including potential treatment
targets.
- Define key components of effective early diagnosis of pulmonary complications secondary to SSc, and implement critical risk assessment.
- Evaluate current strategies for early intervention in PAH and assess related new clinical trial evidence.
- Establish long-term goals and determine the potential utility of emerging combination treatment paradigms in PAH.
Author Disclosures Richard M. Silver, MD
Disclosure: Grant/Research Support: Actelion Pharmaceuticals US and Genentech, Inc; Consultant: Celgene Corporation and Millennium Pharmaceuticals, Inc.; Speakers' Bureau: Actelion Pharmaceuticals US and Genentech, Inc
Richard N. Channick, MD,
FCCP
Disclosure: Grant/Research Support, and/or Consultant or Speakers' Bureau: Actelion Pharmaceuticals US, Gilead Sciences, Inc., United Therapeutics
Kristin B. Highland, MD
Disclosure: Grant/Research Support and/or Speakers’ Bureau: Actelion Pharmaceuticals US, Encysive Pharmaceuticals, Gilead Sciences, Inc., United Therapeutics
Myung H. Park, MD, FACC
Disclosure: Consultant: Actelion Pharmaceuticals US, Gilead Sciences, Inc., United Therapeutics; Speakers’ Bureau: Actelion Pharmaceuticals US, Gilead Sciences, Inc., United Therapeutics
Robert W. Simms, MD
Disclosure: Grant/Research Support: Encysive Pharmaceuticals; Consultant: Millennium Pharmaceuticals, Inc.; Speakers' Bureau: Actelion Pharmaceuticals US
Off-label Product Discussion
Dr Simms
has indicated that his presentation may reference off-label uses for bosentan in scleroderma-associated digital ulcers and phosphodiesterase inhibitors in the treatment of Raynaud's disease and digital ulcers.
|
 |
Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials and Standards.
Medical Education Resources designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
